Abstract

BackgroundA recent randomized controlled trial in patients with rheumatoid arthritis (RA) showed non-inferiority of clinical benefit when starting on triple therapy (sulfasalazine (SSZ)+hydroxychloroqiune (HCQ)+methotrexate (MTX)) as compared to etanercept (ETN)...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.
Jeffrey R Curtis ... Chia‐Chen Teng
Arthritis care & research | VOL. 71
Jeffrey R Curtis, et. al.Jeffrey R Curtis ... Chia‐Chen Teng
30 Aug 2019
FRI0113 Persistence and Adherence with Triple Therapy and Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy in us Veterans with Rheumatoid Arthritis
B Sauer ... D.H Tang
Annals of the Rheumatic Diseases | VOL. 74
B Sauer, et. al.B Sauer ... D.H Tang
01 Jun 2015
Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Jeffrey Greenberg ... George W Reed
Arthritis care & research | VOL. 73
Jeffrey Greenberg, et. al.Jeffrey Greenberg ... George W Reed
30 Jul 2021
Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study.
Seoyoung C Kim ... Rishi J Desai
Arthritis care & research | VOL. 72
Seoyoung C Kim, et. al.Seoyoung C Kim ... Rishi J Desai
29 Sep 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers